

DAFTAR PUSTAKA

- Alcaide, F., Pfyffer, G.E and Telenti, A., 1997. Role of *embB* in Natural and Acquired Resistance to Ethambutol in Mycobacteria. *Antimicrob. Agents Chemother.* 41: 2270 – 2273.
- Bardou, F., Raynaud, C., Ramos, C., Lane'elle, M.A and Lane'elle, G. 1998. Mechanism of isoniazid uptake in *Mycobacterium tuberculosis*. 1998. *Microbiology* .144:2539–2544
- Bartfai, Z., A. Somoskóvi, Kódmoón, C.N., Szabó, N., Puska's, E., Kosztolányi, L., Farago, R., Mester, J., Parsons, L.M, and Salfinger, M., 2001. Molecular characterization of rifampin-resistant isolates of *Mycobacterium tuberculosis* from Hungary by DNA sequencing and the line probe assay. *J. Clin. Microbiol.* 39:3736–3739
- Basso, L. A., R. Zheng, J. M. Musser, W. R. Jacobs, Jr., and J. S. Blanchard. 1998. Mechanisms of isoniazid resistance in *Mycobacterium tuberculosis*: enzymatic characterization of enoyl reductase mutants identified in isoniazid resistant clinical isolates. *J. Infect. Dis.* 178:769–775.
- Berlitta F et al, 2013, Genetic Variability of *Mycobactrium tuberculosis* in Patients with no known Risk Factor for MBR-TB in the North-eastern partof Lima, Peru. *BMC Infection Diseases*, vol 13, p 397.
- Depkes RI, 2008, Pedoman Nasional Penanggulangan Tuberkulosis, Jakarta, edisi 2, 3-8
- Francis. J. Curry, 2004, Drug Resistant Tuberculosis, a Survival Guide for Clinicians, National Tuberculosis Center, California p 1-15.
- Haeili, M, et al., 2013, Spoligotyping and Drug Resistance Patterns of *Mycobacterium tuberculosis* Iasolates from Five Provinces of Iran, *Microbiology Open* 2(6): 988-996.
- Hanekom, M., van der Spuy,G.D., Streicher, E., Ndbambi, S.L., McEvoy, C.R.E., Kidd, M., Beyers, T., Victor, T.C., van Helden,P.D and Warren, R.M., 2007. A Recently Evolved Sublineage of the *Mycobacterium tuberculosis* Beijing Strain Family Is Associated with an Increased Ability to Spread and Cause Disease. *J. Clinn. Microbiol.* 45: 1483 – 1490.

- Hilleman, D., Weizenegger, M., Kubica, T., Eichter, E and Niemann, S., 2005. Use of the Genotype MTBDR Assay for Rapid Detection of Rifampin and Isoniazid Resistance in *Mycobacterium tuberculosis* Complex Isolates. *J. Clin. Microbiol.* 43: 3699 – 3703.
- Indonesia is Associated with Drug Resistance Gen Mutations in *katG*, *rpoB* and *embB* in Factors Underlying the Success of the *Mycobacterium tuberculosis* Beijing Genotype in Indonesia, chapter 4, 31- 43.
- Kamerbeek, J., Scouls, L., Kolk, A., van Agterveld, M., van Solingen, D., Kuijper, S., Bunschoten, A., Molhouzen, H., Shaw, R., Goyal, M andvan Embden, J., 1997. Simultaneous Detection and Strain Differentiation of *Mycobacterium tuberculosis* for Diagnosis and Epidemiology. *J. Clin. Microbiol.* 35 : 907 – 914.
- Kemenkes RI, 2014, Pedoman Nasional Pengendalian Tuberkulosis, Dirjen P2PL Jakarta.
- Kemenkes RI, 2014, Petunjuk Teknis Manajemen Terpadu Pengendalian Tuberkulosis Resisten Obat, Dirjen PP & PL, Jakarta.
- Kemenkes RI, 2015, Manajemen Terpadu Pengendalian Tuberkulosis Resisten Obat (MTPTRO), Tb Indonesia , Jakarta.
- Kisa. O, et al, 2012, Distribution of Spoligotyping Defined Genotypic Lineages Drug-resistant *Mycobactrium tuberculosis* Complex Clinical Isolates in Ankara, Turkey, *Plos One*, vol 7, 2012.
- Lee, A. S. G., A. S. M. Teo, and S. Y. Wong. 2001. Novel mutations in *ndh* in isoniazid-resistant *Mycobacterium tuberculosis* isolates. *Antimicrob. Agents Chemother.* 45:2157–2159
- Marrakchi, H., G. Laneelle, and A. Quemard. 2000. InhA, a target of the antituberculosis drug isoniazid, is involved in a mycobacterial fatty acid elongation system, Fas-II. *Microbiology* 146:289–296.
- Miesel, L., T. Weisbrod, J. A. Marcinkeviciene, R. Bittman, P. Doshi, J. C. Sacchettini, and W. R. Jacobs, Jr. 1998. NADH dehydrogenase defects confer resistance to isoniazid and conditional lethality in *Mycobacterium smegmatis*. *J. Bacteriol.* 180:2459–2467
- N Engl, 2003, Current Concept Molecular Epidemiology of Tuberculosis, Journal Mid 349;12.

Nguyen,D, et al, 2004, Genomic Characterization of an Endemic Mycobacterium tuberculosis Strain : Evolutionary and Epidemiologic Implications, Journal of Clinical Epidemiology, June, p 2573 – 2580.

Pang, Y, et al, 2012, Spoligotyping and Drug Resistance Analysis of *Mycobacterium tuberculosis* Strains from National Survey in China, Plos ONE 7(3).

Parwati, I, 2008, et al, Mycobacterium tuberculosis Beijing Genotype in Parwati, I., van Crevel, R., Sudiro, M., Alisjahbana, B., Pakasi, T., Kremer, K., van Zanden, A and van Soolingen, D., 2008. The population structure of Mycobacterium tuberculosis differs significantly on two Indonesian Islands. J. Clin.Microbiol. 46: 3639 – 3642.

Paul D van Helden *at al*, 2012, Straian Families of Mycbacterium tuberculosis, Departement of Medical Biochemistry, University of Stellenbosch School, Tygerberg, South Africa.

Ramaswamy, S.V., Reich, R., Dou, SJ., Jasperse, L., Pan, X., Wanger, A., Quitugua, T and Graviss, E.A., 2003. Single Nucleotide Polymorphisms in Genes Associated with Isoniazid Resistance in *Mycobacterium tuberculosis*. Antimicrob. Agents Chemother. 47: 1241 – 1250.

Rattan, A., Kalia, A and Ahmad, N., 1998. Multidrug-Resistant Mycobacterium tuberculosis: Molecular Perspectives. *Emerg. Infect. Dis.* 4: 195 – 209.

Scorpio A and Zhang Y., 1996. Mutations in *pncA*, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus. Nat Med 2: 662-667.

Scorpio A, Lindholm-Levy P, Heifets L, Gilman R, Siddiqi S, Cynamon M, Zhang Y., 1997. Characterization of *pncA* mutations in pyrazinamide resistant *Mycobacterium tuberculosis*. *Antimicrob Agents Chemother* . 41: 540-542.

Sherman, D. R., K. Mdluli, M. J. Hickey, T. M. Arain, S. L. Morris, C. E. Barry III, and C. K. Stover. 1996. Compensatory *ahpC* gene expression in isoniazid-resistant *Mycobacterium tuberculosis*. Science 272:1641–1643

Solomon, G et al, Drug Resistant Mucobactrium tuberculosis of the Beijing Genotype Does Not Spread in Sweden, Plos One, 2011.

Sreevatsan S, Pan X, Zhang Y, Kreisworth BN, Musser JM., 1997. Mutations associated with pyrazinamide resistance in *pncA* of *Mycobacterium tuberculosis* complex organisms. *Antimicrob Agents Chemother*. 41: 36-40.

Sreevatsan, S., X. Pan, Y. Zhang, V. Deretic, and J. M. Musser. 1997. Analysis of the *oxyR-ahpC* region in isoniazid-resistant and -susceptible *Mycobacterium tuberculosis* complex organisms recovered from diseased humans and animals in diverse localities. *Antimicrob. Agents Chemother.* 41: 600–606.

Tracevska, T. et al. 2004. A Ribosomal Mutation in Streptomycin Resistant *Mycobacterium tuberculosis* Isolates, *J. Infect. Dis.* 167 : 1505–1506).

Victor, T.C., van Rie, A., Jordaan, A.M., Richardson, M., van der Spuy, G., Beyers, N., van Helden, P and Warren, R., 2001. Sequence Polymorphism in the *rrs* Gene of *Mycobacterium tuberculosis* Is Deeply Rooted within an Evolutionary Clade and Is Not Associated with Streptomycin Resistance. *J. Clin. Microbiol.* 39 : 4184 – 4186.

Vivi Lisdawati, dkk., 2010. Studi Pemetaan Awal DNA *Mycobacterium tuberculosis* Complex Secara Spoligotyping pada Hasil Isolasi Dahak Pasien Tuberkulosis Paru dari 10 Ibu Kota Propinsi (Bagian I), *Buletin Penelitian Kesehatan*, Vol. 38, No. 4, 2010 : 169-185.

Wengenack, N. L., and F. Rusnak. 2001. Evidence for isoniazid-dependent free radical generation catalyzed by *Mycobacterium tuberculosis* KatG and the isoniazid-resistant mutant KatG(S315T). *Biochemistry* 40:8990–8996

Weyer, K., Lancaster, J., Brand, J., van der Walt, M and Levin, J., 2004. Survey of tuberculosis drug resistance in South Africa 2001–2002. Final report. MRC, Pretoria, South Africa. <http://www.sahealthinfo.org/tb/natsurvey.pdf>.

WHO, 2005. Global tuberculosis control; Survailance, planning and financing. WHO report. Jenewa.

WHO, 2014, Global Status Report, Genewa.

Yati H. Istiantoro,. Rianto Setiabudy, 2007, Tuberkulostatik dan Leprostatik, dalam Famakologi dan Terapi, edisi 5, 613-637, Departemen Farmakologi dan Terapeutik FK-UI, Jakarta.

Adjers-Koskela, K., Katila, M.-L., 2003. Susceptibility testing with the manual mycobacteria growth indicator tube (MGIT) and the MGIT 960 system provides rapid and reliable verification of multidrug-resistant tuberculosis. *J. Clin. Microbiol.* 41, 1235– 1239.

Affolabi, D., Sanoussi, ND., Odoun, M., Martin, A., Koukpemedji, L., Polomino, J.C, Kestens, L., Anagonou, S and Portaels, F., 2008. Rapid detection of multidrug-resistant *Mycobacterium tuberculosis* in Cotonou (Benin) using two low-cost colorimetric methods: resazurin and nitrate reductase assays. *J. Med. Microbiol.* 57: 1024–1027

Angeby, K.A.K., Klintz, L and Hoffner, S.E., 2002. Rapid and Inexpensive Drug Susceptibility Testing of *Mycobacterium tuberculosis* with a Nitrate Reductase Assay. *J. Clin. Microbiol.* 40 : 553 – 555

Bemer, P., Bodmer, T., Munzinger, J., Perrin, M., Vincent, V and Drugeon, H., 2004. Multicenter Evaluation of the MB/BACT System for Susceptibility Testing of *Mycobacterium tuberculosis*. *J. Clin. Microbiol.* 42 : 1030 – 1034.

Bergmann, J. S., and G. L. Woods. 1998. Evaluation of the ESP Culture System II for testing susceptibilities of *Mycobacterium tuberculosis* to four primary antituberculous drugs. *J. Clin. Microbiol.* 36:2940–2943.

Brunello, F., and R. Fontana. 2000. Reliability of the MB/BACT System for testing susceptibility of *Mycobacterium tuberculosis* complex strains to antituberculous drugs. *J. Clin. Microbiol.* 38:872–873.

Caviedes, L., Delgado, J and Gilman, R.H., 2002. Tetrazolium Microplate Assay as a Rapid and Inexpensive Colorimetric Method for Determination of Antibiotic Susceptibility of *Mycobacterium tuberculosis*. *J. Clin. Microbiol.* 40: 1873–1874.

Caviedes, L., Lee, T.S., Gilman, R.H., Sheen, P., Spellman, E., Lee, E.H., Berg, D.E., Montenegro-James, S., 2000. Rapid, efficient detection and drug susceptibility testing of *Mycobacterium tuberculosis* in sputum by microscopic observation of broth cultures. *J. Clin. Microbiol.* 38:1203–1208.

Coban, A.Y., Bilgin, J., Uzun, M., Fisgin, N.T., Akgunes, A., Cihan, C.C., Birinci, A and Durupinar, B., 2005. Susceptibilities of *Mycobacterium tuberculosis* to Isoniazid and Rifampin on Blood Agar. *J. Clin. Microbiol.* 43 : 1930 – 1931.

Drancourt, M., P. Carrieri, M.-J. Ge'vaudan, and Raoult D. 2003. Blood agar and *Mycobacterium tuberculosis*: the end of a dogma. J. Clin. Microbiol. 41:1710–1711.

van Embden, JD., Cave, MD., Crawfor, JT., Dale, JW., Eisenach, KD., Gicquel, B. 1993. Strain identification of *Mycobacterium tuberculosis* by DNA fingerprinting:P recomendation for standart technology. J Clin Microbiol. 31:406-9.

Franzblau, S. G., Witzig, R.S., McLaughlin, J.C., Torres, P., Madico, G., Hernandez, A., Degnan, M.T., Cook, M.B., Quenzer, V.K., Ferguson, R.M and Gilman, R.H., 1998. Rapid, low-technology MIC determination with clinical *Mycobacterium tuberculosis* isolates by using the microplate Alamar Blue assay. J. Clin. Microbiol. 36:362–366

Golyshevskaia, V. I., A. A. Korneev, L. N. Chernousova, L. G. Selina, T. A. Kazarova, T. D. Grishina, S. G. Safonova, V. A. Puzanov, G. M. Nikolaeva, and N. I. Fadeeva. 1996. New microbiological techniques in diagnosis of tuberculosis. Probl. Tuberk. 6:22–25

Goude, R., Amin, A.G., Chaterjee, D and parish, T., 2008. The Critical Role of *embC* in *Mycobacterium tuberculosis*. J. Bacteriol. 190 : 4335 – 4341.

Grandjean, L., Martin, L., Gilman, R.H., Valencia, T., Herrera, B., Quino, W., Ramos, E., Rivero, M., Montoya, R., Escombe, A.R., Coleman, D., Mitchison, D and Evans, C.A., 2008. Tuberculosis Diagnosis and Multidrug Resistance Testing by Direct Sputum Culture in Selective Broth without Decontamination or Centrifugation. J. Clin. Microbiol. 45: 2339 – 2344.

Kong, Y., Cave, M.D., Zhang, L., Foxman, B., Marrs, C.F., Bates, J.H and Yang, Z.H., 2007. Association between *Mycobacterium tuberculosis* Beijing/W Lineage Strain Infection and Extrathoracic Tuberculosis: Insights from Epidemiologic and Clinical Characterization of the Three Principal Genetic Groups of *M. tuberculosis* Clinical Isolates. J. Clin. Microbiol. 45:409 – 414.

Kontos, F., Maniati, M., Costopoulos, C., Gitti, Z., Nicolaou, S., Petinaki, E., Anagnostow, S., Tselenti, I and Maniatis, A.N., 2004. Evaluation of the fully automated Bactec MGIT 960 system for the susceptibility testing of *Mycobacterium tuberculosis* to first-line drugs: a multicenter study. Microbiol. Method. 56 :291 – 294.

- Kremer, K., Glynn, J.R., Lillebaek, T., Niemann, S., Kurepina, N.E., Kreiswirth, B.N., Bifani, P.J and van Soolingen, D., 2004. Definition of the Beijing/W Linkage of *Mycobacterium tuberculosis* on the basis of genetic markers. *J. Clin. Microbiol.* 42 : 4040 – 49.
- Martin, A., Poertaels, F and Polomino, J.C., 2007. Colorimetric redox-indicator methods for the rapid detection of multidrug resistance in *Mycobacterium tuberculosis*: a systematic review and meta-analysis. *J. antimicrob. chem.* 59 : 175 – 183.
- Moore, D. A., C. A. Evans, R. H. Gilman, L. Caviedes, J. Coronel, A. Vivar, E. Sanchez, Y. Pinedo, J. C. Saravia, C. Salazar, R. Oberhelman, M. G. Hollm-Delgado, D. LaChira, A. R. Escombe, and J. S. Friedland. 2006. Microscopic-observation drug-susceptibility assay for the diagnosis of TB. *N. Engl. J. Med.* 355:1539–1550.
- National Committee for Clinical Laboratory Standards, 2000. Susceptibility testing of mycobacteria, nocardia, and other aerobic actinomycetes. Tentative Standard M24-T2, 2nd. ed. NCCLS.
- Roberts, G. D., Goodman, N. L., Heifets, L., Larsh, H. W., Lindner, T. H., McClatchy, J. K., McGinnis, M. R., Siddiqi, S. H. & Wright, P..1983. Evaluation of the BACTEC radiometric method for recovery of mycobacteria and drug susceptibility testing of *Mycobacterium tuberculosis* from acid-fast smear-positive specimens. *J. Clin. Microbiol.* 18: 689–696.
- Streicher, E.M., Victor, T.C., van der Spuy, G., Sola, C., Rastogi, N., van Helden, P.D and Warren, R.M., 2007. Spoligotype Signatures in the *Mycobacterium tuberculosis* Complex. *J. Clin. Microbiol.* 45 : 237 – 240.
- Sun, Y. J., A. S. Lee, S. Y. Wong, and N. I. Paton. 2006. Association of *Mycobacterium tuberculosis* Beijing genotype with tuberculosis relapse in Singapore. *Epidemiology. Infect.* 134:329–332.
- van Soolingen, D., L. Qian, P. E. de Haas, J. T. Douglas, H. Traore, F. Portaels, H. Z. Qing, D. Enkhsaikan, P. Nymadawa, and J. D. van Embden. 1995. Predominance of a single genotype of *Mycobacterium tuberculosis* in countries of east Asia. *J. Clin. Microbiol.* 33:3234– 3238
- Tortoli, E., Benedetti, M., Fontanelli, A., Simonetti, M.T., 2002. Evaluation of automated BACTEC MGIT 960 system for testing susceptibility of *Mycobacterium tuberculosis* to four major antituberculous drugs:

comparison with the radiometric BACTEC 460 TB method and the agar plate method of proportion. J. Clin. Microbiol. 40, 607–610

Bardou, F., Raynaud, C., Ramos, C., Lane'elle, M.A and Lane'elle, G. 1998. Mechanism of isoniazid uptake in *Mycobacterium tuberculosis*. 1998. Microbiology .144:2539–2544

Berlitta F et al, 2013, Genetic Variability of *Mycobactrium tuberculosis* in Patients with no known Risk Factor for MBR-TB in the North-eastern partof Lima, Peru. BMC Infection Diseases, vol 13, p 397.

Hilleman, D., Weizenegger, M., Kubica, T., Eichter, E and Niemann, S., 2005. Use of the Genotype MTBDR Assay for Rapid Detection of Rifampin and Isoniazid Resistance in *Mycobacterium tuberculosis* Complex Isolates. J. Clin. Microbiol. 43: 3699 – 3703.

Indonesia is Associated with Drug Resistance Gen Mutations in *katG*, *rpoB* and *embB* in Factors Underlying the Success of the *Mycobacterium tuberculosis* Beijing Genotype in Indonesia, chapter 4, 31- 43.

Kisa. O, et al, 2012, Distribution of Spoligotyping Defined Genotypic Lineages Drug-resistant *Mycobactrium tuberculosis* Complex Clinical Isolates in Ankara, Turkey, Plos One, vol 7, 2012.

Pang, Y, et al, 2012, Spoligotyping and Drug Resistance Analysis of *Mycobacterium tuberculosis* Strains from National Survey in China, Plos ONE 7(3).

Parwati, I, 2008, et al, Mycobacterium Tuberculosis Beijing Genotype in Parwati, I., van Crevel, R., Sudiro, M., Alisjahbana, B., Pakasi, T., Kremer, K., van Zanden, A and van Soolingen, D., 2008. The population structure of *Mycobacterium tuberculosis* differs significantly on two Indonesian Islands. J. Clin. Microbiol. 46: 3639 – 3642.

Ramaswamy, S.V., Reich, R., Dou, SJ., Jasperse, L., Pan, X., Wanger, A., Quitugua, T and Graviss, E.A., 2003. Single Nucleotide Polymorphisms in Genes Associated with Isoniazid Resistance in *Mycobacterium tuberculosis*. Antimicrob. Agents Chemother. 47: 1241 – 1250.

Solomon, G et al, Drug Resistant Mucobactrium tuberculosis of the Beijing Genotype Does Not Spread in Sweden, Plos One, 2011.

Vivi Lisdawati, dkk,2010. Studi Pemetaan Awal DNA *Mycobacterium tuberculosis* Complex Secara Spoligotyping pada Hasil Isolasi Dahak

Pasien Tuberkulosis Paru dari 10 Ibu Kota Propinsi (Bagian I), Buletin Penelitian Kesehatan, Vol. 38, No. 4, 2010 : 169-185.

Wengenack, N. L., and F. Rusnak. 2001. Evidence for isoniazid-dependent free radical generation catalyzed by *Mycobacterium tuberculosis* KatG and the isoniazid-resistant mutant KatG(S315T). *Biochemistry* 40:8990–8996

Weyer, K., Lancaster, J., Brand, J., van der Walt, M and Levin, J., 2004. Survey of tuberculosis drug resistance in South Africa 2001–2002. Final report. MRC, Pretoria, South Africa.
<http://www.sahealthinfo.org/tb/natsurvey.pdf>.

Yati H. Istiantoro,, Rianto Setiabudy, 2007, Tuberkulostatik dan Leprostatik, dalam Famakologi dan Terapi, edisi 5, 613-637, Departemen Farmakologi dan Terapeutik FK-UI, Jakarta.

